ESMO PracticeUpdate Conference Series:Videos from #ESMO20 on Genitourinary Cancers
Key Takeaways from ESMO: Novel Frontline Therapies for Advanced Bladder Cancer
- There are a number of presentations evaluating novel frontline combinations in bladder cancer. Which are some of the most important studies that are being presented?
- Were there any other key studies in the frontline setting that you'd like to highlight?
- Do any of these studies provide justification for a new standard of care in the frontline setting?
Key Takeaways from ESMO: Updates on Immunotherapy for Bladder Cancer
- What are some of the key studies at this year's ESMO involving the use of immunotherapy for bladder cancer?
- Would you consider sequential therapy with either of these combinations as potentially being effective, or would you just stick with avelumab for the time being?
- Were there any interesting immunotherapy-related trials in later lines of therapy at this year's ESMO?
- What do these results overall suggest about the optimal sequencing of immunotherapy, chemotherapy, or even targeted therapy? - Were there any updates from JAVELIN Bladder 100 that might inform clinical practice?
Key Takeaways from ESMO: highlights from major prostate cancer trials
- Moving to the next key trial on ipatasertib. What can you tell us about this agent?
- Finally, what new information did we get from the STAMPEDE update?
Key Takeaways from ESMO: immunotherapy for renal cell carcinoma
Sumanta Kumar Pal
- What caught your eye in immunotherapy in general for advanced RCC from ESMO 2020?
- Could you dive a little bit more about what these immunotherapy-based combinations presented at ESMO had in impact in terms of toxicities and quality of life for these patients?
Key Takeaways from ESMO: updates in targeted therapy for metastatic renal cell carcinoma
- What are the most important updates regarding targeted therapy for metastatic renal cell carcinoma in this recent ESMO meeting?
- I would like to go a little bit broader on the CheckMate-9ER data. Where do you think that it will fit into the algorithm of treating the renal cell carcinoma, whenever it will get approved?
- About the HIF-2 inhibitor and its role in VHL disease management, previously you also presented the data. Now we have more information about the strengths of this agent in treating VHL disease. Do you think that this will be potentially used in the treatment? And should we consider this only for renal cell carcinoma treatment or also for hemangioblastoma treatment?
The ESMO PU Conference Series – A collaboration brought to you by Elsevier’s PracticeUpdate and the European Society for Medical Oncology.